Proceduren for indbragte sager i henhold artikel 30 i direktiv 2001/ 83/ EF, med senere ændringer, for Risperdal blev indledt for at løse uoverensstemmelser mellem de nationalt godkendte produktresuméer inden for EU- medlemslandene og EØS- landene, specielt med hensyn til afsnittene om indikation, dosering og indgivelsesvej, kontraindikationer, særlige advarsler og forsigtighedsregler vedrørende brugen samt interaktion med andre lægemidler eller andre former for interaktion.
The Referral procedure under Article 30 of Directive 2001/ 83/ EC, as amended for Risperdal was initiated in order to resolve divergences amongst the nationally authorised Product Information texts across the EU and EEA Member States, in particular with respect to the sections on indication, posology and method of administration, contraindications, special warnings and precautions for use and interactions with other medicinal products or other forms of interactions.